Silo Pharma (SILO) has announced the signing of an exclusive, global license agreement with Columbia University aimed at advancing the development, manufacturing, and commercialization of its leading drug candidate, SPC-15. This intranasal treatment targets stress-induced affective disorders and PTSD. The company is currently finalizing the necessary steps to submit an Investigational New Drug (IND) application to the FDA to initiate first-in-human clinical studies.
"We believe that securing the exclusive license agreement for our SPC-15 product represents a crucial milestone for Silo Pharma, potentially enhancing shareholder value pending FDA approval," stated Silo Pharma CEO Eric Weisblum.
